BioAmber Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2015. For the quarter, the company reported total revenues of $1,111,000 compared to $308,000 a year ago. Operating loss was $9,285,000 compared to $9,038,000 a year ago. Loss before income taxes was $8,675,000 compared to $4,306,000 a year ago. Net loss attributable to company shareholders of $7,602,000 compared to $3,953,000 a year ago. Adjusted net loss attributable to company shareholders of $10,389,000, or a loss of $0.40 per share compared to $10,378,000 or a loss of $0.48 per share a year ago.

Revenues for the year ended December 31, 2015 increased to $2.2 million from $1.5 million last year. This included sales of $1.1 million in the fourth quarter of 2015.  Research and development expenses for the year ended December 31, 2015 increased to $20.3 million from $15.2 million last year. The company recorded a net loss attributable to company shareholders of $37.2 million, or a loss of $1.52 per share for the year ended December 31, 2015, compared to a net loss of $46.5 million, or a loss of $2.32 per share last year. The adjusted net loss attributable to company shareholders for the year ended December 31, 2015 was $38.0 million, or a loss of $1.55 per share, compared to an adjusted net loss attributable to company shareholders of $34.7 million, or a loss of $1.74 per share in 2014. Operating loss was $38,528,000 compared to $35,205,000 a year ago. Loss before income taxes was $41,175,000 compared to $47,274,000 a year ago. Net cash used in operating activities was $32,199,000 compared to $22,454,000 a year ago. Acquisition of property and equipment was $64,390,000 compared to $85,014,000 a year ago.